The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...
TRENTON, N.J. — A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over ...
Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary. Objectives: To describe the ...
Please provide your email address to receive an email when new articles are posted on . Among adults with type 2 diabetes, biosimilar insulin was noninferior to insulin glargine for lowering HbA1c, ...
The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...
Mylan and Biocon's Semglee (insulin glargine injection) is now the second approved "follow-on" biologic of Sanofi's Lantus. Adults with Type 2 diabetes, and adult and pediatric patients with Type 1 ...
Original Medicare (Part A and Part B) does not cover insulin glargine (Basagalar). Medicare Part C and Part D cover some forms of insulin if you have diabetes, but coverage depends on the plan‘s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results